Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development

International Journal of Laboratory Hematology

Volumn 33, Issue 3, 2011, Pages 272-280

  Dudek, M M ^a   Harris, L F ^a   Killard, A J ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

APTT; Clotting time; Heparin sensitivity; Stability; Thrombin generation

Indexed keywords

HEPARIN; KAOLIN; PHOSPHOLIPID; REAGENT; SILICON DIOXIDE; THROMBIN;

ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; LIQUID; PARTIAL THROMBOPLASTIN TIME; POINT OF CARE TESTING; PRIORITY JOURNAL; STORAGE;

BLOOD COAGULATION; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; REAGENT KITS, DIAGNOSTIC;

EID: 79954590457     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01283.x     Document Type: Article

References (31)

1. Banez E.I., Triplett D.A. & Koepke J. (1980) Laboratory monitoring of heparin therapy - The effect of different salts of heparin on the Activated Partial Thromboplastin Time - An analysis of the 1978 and 1979 CAP hematology survey. American Journal of Clinical Pathology 74, 569-574.
2. Beguin S., Lindhout T. & Hemker H.C. (1988) The mode of action of heparin in plasma. Thrombosis and Haemostasis 60, 457-462.
3. Bowers J. & Ferguson J.J. (1993) Use of the Activated Clotting Time in anticoagulation monitoring of intravascular procedures. Texas Heart Institute Journal 20, 258-263.
4. Comfurius P., Smeets E.F., Willems G.M., Bevers E.M. & Zwaal R.F.A. (1994) Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine. Biochemistry 33, 10319-10324.
5. Dargaud Y., Luddington R., Gray E., Lecompte T., Siegemund T., Baglin T., Hogwood J., Regnault V., Siegemund A. & Negrier C. (2010) Standardisation of thrombin generation test - which reference plasma for TGT?: an international multicentre study. Thrombosis Research 125, 353-356.
6. Eby C. (1997) Standardization of APTT reagents for heparin therapy monitoring: urgent or fading priority? Clinical Chemistry 43, 1105-1107.
7. Gawoski J.M., Arkin C.F., Bovill T., Brandt J., Rock W.A & Triplett D.A. (1987) The effects of heparin on the Activated Partial Thromboplastin Time of the College of American Pathologists survey specimens - Responsiveness, precision and sample effects. Archives of Pathology & Laboratory Medicine 111, 785-790.
8. Griffin J.H. & Cochrane C.G. (1979) Recent advances in the understanding of the contact activation reactions. Seminars in Thrombosis and Hemostasis 5, 254-273.
9. Jespersen J., Bertina R.M. & Haverkate F. (1999) Laboratory Techniques in Thrombosis: A Manual. Kluwer Academic Publishers B.V., Dordrecht, The Netherlands.
10. Khan T. (2009) Point-of-care INR monitoring devices for patients on long-term oral anticoagulation therapy. Value in Health 12, A142.
11. Kitchen S., Jennings I., Woods T.A.L. & Preston F.E. (1996) Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. Journal of Clinical Pathology 49, 10-14.
12. Kitchen S., Cartwright I., Woods T.A.L., Jennings I. & Preston F.E. (1999) Lipid composition of seven APTT reagents in relation to heparin sensitivity. British Journal of Haematology 106, 801-808.
13. Lo K., Denney W.S. & Diamond S.L. (2005) Stochastic modeling of blood coagulation initiation. Pathophysiology of Haemostasis and Thrombosis 34, 80-90.
14. Mann K.G., Whelihan M.F., Butenas S. & Orfeo T. (2007) Citrate anticoagulation and the dynamics of thrombin generation. Journal of Thrombosis and Haemostasis 5, 2055-2061.
15. Manzato F., Mengoni A., Grilenzoni A. & Lippi G. (1998) Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring. Clinical Chemistry and Laboratory Medicine 36, 975-980.
16. Marlar R.A., Bauer P.J., Endresbrooks J.L., Montgomery R.R., Miller C.M. et al. (1984) Comparison of the sensitivity of commercial aPTT reagents in the detection of mild coagulopathies. American Journal of Clinical Pathology 82, 436-439.
17. Martin B.A., Branch D.W. & Rodgers G.M. (1992) The preparation of a sensitive Partial Thromboplastin reagent from bovine brain. Blood Coagulation & Fibrinolysis 3, 287-294.
18. Moritz B. & Lang H. (1995) APTT in a collective of plasmas from normal healthy individuals - Comparison of Dapttin with other aPTT reagents. Thrombosis and Haemostasis 73, 1243.
19. Okuda M. & Yamamoto Y. (2004) Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clinical and Laboratory Haematology 26, 215-223.
20. Poller L., Thomson J.M. & Taberner D.A. (1989) Use of the Activated Partial Thromboplastin Time for monitoring heparin therapy - Problems and possible solutions. 2nd International Symp on Standardization and Quality Control of Coagulation Tests: Implications for the Clinical Laboratory. Rome, Italy.
21. Shetty S., Ghosh K. & Mohanty D. (2003) Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer. Blood Coagulation & Fibrinolysis 14, 493-497.
22. Slater P.J., Stevenson K.J. & Poller L. (1980) Procoagulant activity of Partial Thromboplastin (cephalin) reagent and its phospholipid composition. Thrombosis Research 18, 831-838.
23. Stevenson K.J., Poller L. & Thomson J.M. (1991) The chemical composition, ultrastructure and procoagulant properties of 5 new aPTT reagents. Thrombosis and Haemostasis 65, 906.
24. Struver G.P. & Bittner D.L. (1962) Partial Thromboplastin Time (Cephalin Time) in anticoagulation therapy. American Journal of Clinical Pathology 38, 473-478.
25. Ts'ao C., Neofotistos D., Oropeza M., Rogan M. & Santos M. (1998) Performance characteristics of a new synthetic APTT reagent. Clinical and Laboratory Haematology 20, 307-313.
26. Van den Besselaar A., Meeuwissebraun J. & Bertina R.M. (1990) Monitoring heparin therapy - Relationships between the Activated Partial Thromboplastin Time and heparin assays based on ex vivo heparin samples. Thrombosis and Haemostasis 63, 16-23.
27. Van den Besselaar A., Neuteboom J., Meeuwissebraun J. & Bertina R.M. (1997) Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clinical Chemistry 43, 1215-1222.
28. Van Veen J.J., Gatt A. & Makris M. (2008) Thrombin generation testing in routine clinical practice: are we there yet? British Journal of Haematology 142, 889-903.
29. Varadi K., Turecek P.L. & Schwarz H.P. (2004) Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 10, 17-21.
30. Wojtkowski T.A., Rutledge J.C. & Matthews D.C. (1999) The clinical impact of increased sensitivity PT and APTT coagulation assays. American Journal of Clinical Pathology 112, 225-232.
31. Wolberg A.S. (2007) Thrombin generation assays: understanding how the method influences the results. Thrombosis Research 119, 663-665.